Meeting Coverage

Patients with gout have significantly greater intercritical inflammation and lumbosacral spine monosodium urate crystal (MSU) deposition when compared with those without the condition, and trend toward greater deposition among...

Pegloticase is effective for lowering serum urate patients with uncontrolled or refractory gout, although more than half of patients experience anti-drug antibody development which limits its efficacy.1 Administering pegloticase...

The American Society of Hematology Annual Meeting & Exposition (ASH 2021) Will be held December 11-14, 2021 at the Georgia World Congress Center in Atlanta, as well as virtually. The “premier event in malignant and...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Representative Rosa DeLauro (D-CT) for her outstanding support of hematology research at the 2021 ASH Annual Meeting, December 11-14, in Atlanta,...

(WASHINGTON, Nov. 22, 2021) – The American Society of Hematology (ASH) will honor Peter Marks, MD, PhD, Director of the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) for his...

MIRROR RCT (NCT03994731) phase III data support the combination of immunosuppression with pegloticase treatment for uncontrolled gout in all patients, raising the response rate from 40-42% to 71%. Physician’s Weekly spoke with...

In the phase IV open-label PROTECT trial of pegloticase therapy (pegylated recombinant uricase) in treating severe gout in renal transplant recipients, 89% of patients achieved the primary endpoint of serum uric acid (sUA) less...

We recently spoke with Andrea Lora Kossler, MD, FACS, from the Byers Eye Institute at Stanford University about results from the study “Effect of Teprotumumab on Ocular Surface Disease in Active Thyroid Eye Disease,” which she...

Physician’s Weekly spoke recently with Roman Shinder, MD, FACS, from the Departments of Ophthalmology and Otolaryngology at SUNY Downstate Medical Center, about study results he and his colleague, Anna Artymowicz, MD, presented...

Patients with active psoriatic arthritis are better off with monotherapy with ustekinumab compared with the combination of methotrexate and ustekinumab. The combination causes more side effects and does not enhance efficacy or...

People with difficult-to-treat rheumatoid arthritis who do not have success with one JAK inhibitor could succeed either by cycling to other JAK inhibitors or switching to a biologic. Both strategies led to comparable control of...

Tigulixostat was successfully tested in patients with gout and hyperuricemia for its serum urate-lowering capacity. The drug was overall well tolerated and without particular safety signals. These results support dose finding...

A retrospective chart review analysis in the first 24 hours after hospital admission revealed four predictors that discriminate between children with multisystem inflammatory syndrome and other syndromes: hypotension, abdominal...

Patients with rheumatoid arthritis and associated interstitial lung disease could be safely treated with pirfenidone, the TRAIL1 study showed. In participants receiving the antifibrotic, lung function decline was slowed down,...

A genome-wide association study (GWAS) of dry eye (DE) suggests DE-associated single nucleotide polymorphisms (SNPs) are correlated with increased ocular pain and comorbidities, but not with DE signs, according to study...

Several significant advances have occurred in dry eye disease (DED) treatment in recent years, according to Amy Lin, MD. Including treatments with novel mechanisms of action and delivery systems. “This news is very exciting for...